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The pathways of blood coaguiation
DooR DR. H. C. HEurrn
Folia Medica Neerlandica-Vol. I0l4-5, 1967.
In 1963 Mlcr.rnr-aNB published a theory on the
reaction mechanism of blood coagulation known
as the cascade hypothesisss. A short time later,
Davns and R.q,rNorF made a similar suggestion8.
The cascade hypothesis can be viewed as a syn-
thesis of the knowledge in the field of the bio-
chemistry of blood coagulation* at that moment
and as aunifying theory of the interaction of blood
clotting enzymes. The experimental evidence on
which this theory was based has been presented
in various articles36,37. There is iittle doubt that
along general lines this theory presents the best
over-all view of present ideas on the blood coa-
gulation reaction scheme. Within its broad struc-
ture, however, a considerable amount of detailed
investigation remains to be done.
In the present review I will first state the cas-
cade theory and then discuss some recent elabo-
rations and modifications of it. The theory con-
tains sufficient information on coagulation che-
mistry for all purposes except specialized research.
The basis of the cascade theory is the concept
of sequential activation. This concept is perhaps
best explained in terms of an example using well-
known enzymes. The proteolytic enzyme chymo-
trypsin (8.C. l.+.+.S,where E.C. stands for En-
zyme Codel?) is known to originate from the
inactive zymogen chymotrypsinogen. The acti-
vation of chymotrypsinogen occurs by splitting
of the chymotrypsinogen molecule into two parts.
One of these parts is the active chymotrypsin
molecule and the other is a peptide which, as long
as it was part of the zymagen, had been masking
the active site of the chymotrypsin pre-existent
in the chymotrypsinogen. This reaction is repre-
sented in Fig. r.
Now, the splitting of the protein molecule
chymotrypsinogen into an active and an inactive
part is, in itself, a proteolytic action. So we need
not be surprised that a proteolytic enzyme like
trypsin (E.C.Z.+.q.q) can bring about this activa-
tion. Trypsin, however, originates from tryp-
sinogen in a manner analogous to the way in which
chymotrypsin originates from chymotrypsinogen.
Still another proteolytic enzyme, enteropeptidase
@.C.g.+.+.8) can convert trypsinogen into trypsin.
Consequently, the addition of a few molecules
of enteropeptidase to a mixture oftrypsinogen and
chymotrypsinogen would be able to cause the
gradual appearance oftrypsin, and since the tryp-
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Fig. l. A proteolytic enzyme converting a zymogen
into an active enzyrne.
From the Haelnatology Section of the Department of Internal
Manuscript received April 1967.
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Fig. z. A simple enzyme cascade.
Medicine, University llospital, kiden.
sin would act on the chymotrypsinogen, chlnno-
trypsin would arise in the mixture more and more
rapidly.
For the sake of argument this situation has been
simplifled somewhat, but in general this course
of events is perfectly feasible?. If we denote the
zymogen by its initial, and the active enzyme
derived from the zymogen by the same letter with
the subscript a, the reaction sequence just des-
cribed can be represented as in Fig. z. This ex-
ample demonstrates two facts: In the flrst place,
sequential activation is possible in well-defined
biochemical systems; and in the second place,
sequential activation has an amplifying effect
upon the rate of appearance of the final product.
This latter point will not be explained at length
here because it is easily seen intuitively; a theore-
tical treatment of the kinetics involved has been
given elsewherele,3l.
The cascade theory applies the concept of
sequential activation to the blood-coagulation
zymogens and enzymes, or blood-clotting factors
as they are usually called. A clotting factor is
defined as an entity lacking in the plasma of
patients with certain circumscript disorders of
their clotting mer.:hanism. In order to permit the
recognition of a new clotting factor, a coagulation
defect must differ from the defects caused by a
deficiency of previously described clotting factors,
The disorder of two patients is, by definition,
unequal when their plasmas, after mixing, show
correction of the coagulation tests by which the
plasmas have been judged abnormal and equal
when such a correction does not take place.
Furthermore, all known coagulation-factor-de-
ficiencies appear to be caused by different defects
in genetic material as judged from the way in
which these ilLnesses are inherited60.
Most factors have never been prepared in a
sufficiently pure state in the quantities necessary
to determine enough chemical or physico-chemi-
cal properties to define them unambiguously in
this way. Nevertheless, for several clotting factors
the molecular weight, amino-acid composition,
electrophoretic mobility, etc. have been deter-
mined. If nothing else, these results show that
clotting factors are indeed plasma proteins. After
the extraordinary progress made in biochemical
genetics in recent years, it may be questioned
whether a genetical definition, which the clotting
factors do have, does not provide just as good a
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basis for the recognition of a protein as would
physico-chemical determinations-which are still
largely lacking for the clotting factors.
Because an enzyme is defined as a protein with
catalytic propertieslo and because the activated
clotting factors do indeed have catalytic properties
since they catalyse the formation of thrombin
from prothrombin, clotting factors fit perfectly
into the definition of enzymes. Their inactive pre-
cursors would then be zymogens. Yet even ex-
tremely competent enzymologists who are not
especially familiar with the field of blood clotting
hesjtate to recognize them as suchlo and conse-
quently the blood-clotting enzymes (except hrom-
binE.C3.4.4.13) are not mentioned in the list of
known enzymes published by the Commission on
Enzymesl?.
The lnternational Committee on Hemostasis
and Thrombosis solved the ambiguities in the
nomenclature of bloodclotting factors by assign-
ing roman numerals to the factors whose existence
has been well established. A list of these numbers.
together with current synonyms, is given in
Table I.
Put briefly, the casca.de theory of Macplnr-aun
depicts the interaction of these factors as follows:
Contact with a foreign surface converts Factor
XII into an active enzyme, denoted as Factor
Xll.. This errzyme then activates Factor XI,
Factor XI' converts Factor IX, and so on, accord-
ing to the scheme shown in Fig. 3, until finally
thrombin produces fibrin from flbrinogen.
TAer-r I: Norr.tnNcLnturE oF BLooD-cLorrrNG FAcroRs
factor name
I Fibrinogen
il Prothrombin (thrombin is IIu)
III Tissue factor
IV Ca++-ion
V Pro-accelerin
VI Accelerin, identical to V.
VII Proconvertin
Vm Antihaemophilic factor A
IX Christmas factor, antihaemophilic factor B
X Stuart-Prower factor
XI FTA, plasma thromboplastin antecedent
XII HF, Hageman factor
XIII FSF, fit rin-stabilizing factor
? Tatsumi facior
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Fig. :. The clotting cascade.
The clotting time of normal decalcifled plasma
after recalcification (recalcification time) is of the
order of magnitude of several minutes, say 24o
seconds. After addition of a tissue extract, such
as can be derived from the brain, lung, placenta,
or other organs, this time decreases to about 15
seconds (the time thus obtained is called pro-
thrombin time). Plasma deficient in orre of the
Factors XII, XI, IX, or VIII has a considerably
longer recalciflcation time than normal plasma,
but the prothrombin time is equal to that of nor-
mal plasma. On the other hand, Factor VII-de-
flcient plasma has a recalcification time that is
about normal but a prothrombin time as long as
its recalcification time. In Factor I, II, V, and X
deficiencies both recalcification time and pro-
thrombin time are prolonged as compared to
normal plasma. these findings are sufficiently
explained if we assume that an entity in the tissue
extract together with Factor VII has the same
action as the combined Factors XII, XI, IX, and
VIII. In the cascade scheme this is rendered by a
branching at the level of Factor X. Because the
pathway of X activation via tissue factor and
Factor VII reqoires the presence of a "tissue
factor"' extraneous to normal plasma, it is called
Ihe " extr in,s ic pathway"s.
The first reaction of the intrinsic pathway has
been demonstrateC most elegantly by VnoueN3s'
Folia Med. Neerl., ro ( 1967)
62, who was able to demonstrate by the use of an
ellipsometer* that Factor XII attaches to certain
surfaces and after adsorption is removed from the
surface by Factor XI. This irnplies that upon
absorption on these surfaces Factor XII changes
its tertiary structure (i.e. the way in which its poly-
peptide chain is folded), and after this change is
capable of interaction with Factor Xl. This be-
haviour explains why blood begins to clot when
brought into contact with foreign surfaces. Factor
XII has been rather well deflned by the work of
ScnorNrra.rBns et al.a?'ag'as . as a sialoglycoprotein
with esterase and proteolytic properties. Activated
Factor XI also has esterase properties but ones
differing from those of Factor Xllase. ScnoBN-
MAKERS et al. have also found suggestive evidence
that the final active entity arising from the inter-
action of the Factors XII. and Xl is a complex
consisting of both proteins, rather than activated
Factor XI arising from Factor Xl by enzymic
action of activated Factor XIl. The flnal active
entity will be called contact product here, with
negation of the question of its actual composition.
Not many pertinent data are available about
Factor IX. Like most other factors it is a plasma
protein synthesized by the liver. It is defined as
the factor lacking in haemophilia B. Together
with Factors II, VII, and X, it can be separated
from plasma rather easily, and the product thus
obtained corrects plasmas with Factor II, VII,
X or lX deficiencies in vito and raises their
blood level in vivo4'53'55 . The separation of Factors
il, Vn, IX, and X from each other has offerec
considerable difficulties, probably because these
factors occur in the form of a molecular complex
2,63. The fact that these activities can be purified
considerably and still stick together in a complex
has even led to a theory, most ardently defended by
Snrcnns, according to which the entities described
by Factors II, VII, IX, and X are in reality one
*An ellipsometer is a devicefor analysingtheproperties
of elliptically polarized light. When parallel polarized
light is reflected on a surface upon which a very thin
layer of material is adsorbed, the reflected light will
be elliptically polarized. The properties of this ellipti-
cally polarized light are determined by the thickness
and the refractive index of the layer adsorbed. Thus
analysis of the state of polarization of the reflected
light yields data that allow determination of the re-
fractive index and thickness of the layer adsorbed (see
also ref. 43).
moleculesl. A close look at the arguments erupt-
ing in the coagulation literature for more than zo
yo4rs2,5r shows that the only real difference in
opinion is, that SsncrRs assumes that the acti-
vities known as Factor II, VII, IX, and X, are
bound covalently (i.e. by 'onormal" chemical
bonds) when not activated, whereas most other
authors think that the binding, if present, is pro-
bably effected by hyfuogen bonds or by interac-
tion of hydrophobic parts of the molecules. The
fact that a test plasma consisting of equal parts
of Factor II- and Factor Vll-deficient plasmas
immediately after mixture shows virtually normal
results of clotting tests, argues strongly in favour
of the latter view. Moreover, recent research has
shown that the factors under discussion can be
separated. In separated form they correct the de-
ficiency of only one kind of deficient plasma. Only
after remixingdo these separate fractions appeax
to exhibit the autocalytic properties originally
described by Srncrns as typical of his "pure"
preparationso. In addition to this, it was found to
be possible to obtain these clotting factors in a
form several times purer than the best prepara-
tions described by Sercnnsz4'45'16. Nevertheless,
the difficulties in this field have resulted in the
failure to sufficiently purify and biochemically
define Factor IX.
Factor IX is thought to be activated by the
contact product. At a recent congress, evidence
was put forward by Japanese workers that still
another factor, called the Tatsumi factor, might
have a place in the scheme between Factors Xl
and IX8. The Tatsumi-factor deficiency was found
in a Japanese family. The properties of this factor
are said to closely resemble those of Factors II,
VII, IX, and X, and it is thought to be the same
factor as the Thorium vulnerable factor. This
may serve to illustrate the fact that postulating
new factors is still a popular pastime in coagulation
research,
Factor VIII has been purified to a great extent
but sufficient physico-chemical information is
still lackinef'58'5e. Jt is defined as the factor absent
in classic haemophilia or haemophilia A.
Factor V has been purified and its molecular
weight and some other properties are knowna2'14.
It is interesting to note that Factors I (fibrinogen),
V, and VIII seem, like Factors II, VII, IX, and Xo
to form a family. Factors I, V, and VIII are often
found together after various isolation procedures.
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Moreover, a role has been claimed for thrombin
in the physiological conversion of Factors V and
VIII during the clotting process; in addition to
which, of course, thrombin is the natural enzyme
acting on Factor I. This is a most interesting point.
Rlpplponr has provided convincing evidence
that Factor VIII as it occurs in plasma is incapable
of participation in the clotting processao. Only
after the action of a very small but detectable
amount of thrombin is Factor VIII from plasma
converted into a form (called VIII1 bij Rlpp.q,-
ronr) that can take part in the clotting reactions.
The subscribed t in the term VII[1 comes from
thrombin. I would prefer to have this subscript
seen as the t of "transient", which would allow us
to use the same subscript in all similar cases. It is
known that Factor V is also modified and activat-
ed by thrombins8, by Russrr,s viper venom, and
possibly by activated Factor WI23.
It is possible that Factors I, V and VIII are
found together in most purification procedures
because a Factor V- I and a Factor VIII- I com-
plex exists in plasma. If this were true, it would
be conceivable that thrombin could bring Factors
V and VIII into a reactive form by converting the
fibrinogen into fibrin and subsequently breaking
up the complex. Factors V and VIII have still
more properties in common; both are absorbable
to hydrophobic surfacesor and both are consumed
during coagulationGl. As will be shown below, the
analogies between Factors V and VIII on the one
hand and Factors X and IX on the other, were
recently found in our laboratory to be even more
striking than had previously been suspected.
These analogies seem to be broad enough to
justify the postulation of a new coagulation
scheme.
Not much is known about the way in which
Factor VIII is inactivated, although the process
has some interesting and uncommon features6a.
Now, every case history of a severe haemophi-
Iiac shows that the absence of Factor \llII very
severely hinders adequate thrombin formation;
and, according to tbe above-mentioned studies
of RAppApoRr, thrombin is necessary for Factor
VIII activation. This leaves us with the qu€stion:
without either hen or egg, where does the genus
gallus come from? A possible solution is found
in the work of ArrvlN and HeMKrnl, who found
that Factor KI and Factor X[ can activate
Factor YII iust as tissue factor can. Therefore"
Folia Med. Neerl., rc ( 1967)
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the sequence of Factors XII- XI- VII- X- V- il*
can generate thrombin in the absence of tissue
factor, but it does so very slowly. The small
amount of thrombin formed by this pathway
may be of no recognizable importance quantita-
tivily, but may be very important indeed q,lalitati-
vely, because it opens up the intrinsic pathway by
its action on Factor VIII. Small amounts of
thrombin may also be important by reason of
their action on Factor V38 and they are certainly
important for thuir action on the blood-platelets2e.
The latter action, however, will not be reviewed
here because blood-clotting pathways are com-
plicated enough rvithout the introduction of
discussions on the complete mechanism of haemo-
stasis. It needs only be mentioned that thrombin
induces the liberation of phospholipids from the
platelets.
It should be kept in mind that any overshooting
ofthe coagulation process rapidly becomes fatal.
Thrombosis and embolism constitute the highest
contribution to death rates in Wegtern societyl6,
most often by impairing the blood supply to the
heart muscle. One of the mechanis'ls by which
excessive activity of the coagulation process is
prevented is illustrated by the reactions involving
Factor VIII. Factor VIIII exists only as a relatively
short-lived substance whose procoagulant power
rapidly vanishes once it has been evoked. This
mechanism is also found for Factor V and Factor
II and it may exist for the Factors XI, X and VII
as wellll. There is also a possib:ility that the very
action of a procoagulant (i.e. an activated clottirrg
factor) triggers the generation of the activities that
will subsequently inactivate this procoagtrlant.
Factor V. at least, has been shown to be broken
down by thrombinso under certain conditions. As
thrombin is an activator of Factor V, we find the
same difficulty here as we encountered with Factor
VIII: How can Factor V be activated to form a
prothrombin-converting enzyme, if thrombin is
needed to make Factor V active?
EsNourl2 has found one answer to this question:
Factor V does not seem to be compulsory for
thrombin formation; it acts only as an accelerator.
In our laboratory we have found another answer:
Not only thrombin but also activated Factor VII
may be able to activate Factor V23.
*The factual correctness of the factor sequence X-V-II
will be discussed below.
Folia Med, Neerl., ro (1967)
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A crucial problem of the blood coagulation
mechanism requires discussionnow: What is the
nature of the enzyme that converts prothrombin?
First, some words about the nomenclature. As
long as the real nature of this enzyme is unknown,
it is best denoted by the name of its substrate
with the suffix -ase. Therefore. we shall call it
prothrombinase or Factor Il-ase. Formerly it
was called "plasma-thromboplastin", especially
when generated via the intrinsic pathway, but this
term is confusing, because in everyday use it ab-
breviates to "thromboplastin" and then no dis-
tinction is possible with respect to tissue-throm-
boplastin, which is the name currently used for
the mixture of tissue-factor and phospholipids
that serves to activate Factor VII and thus to
ensure the activity of the extrinsic pathway.
In the classic cascade schemes, prothrombinase
is thought to be activated Factor V. Macr,qnrrtNr
comes to this postulate by analogy from the other
steps, and states that he cannot yet give experi'
mental evidence for this view3s,
The school of RnrNorr has produced such ex-
perimental evidences'6, although other gtroups have
put forward a considerable body of evidence that
prothrombinase is not constituted from Factor V
alone but from a complex comprising Factors V
and X., Ca++, and phospholipid. At the moment,
the experimental results of R,q.rNorr et al. can
be explained in terms of this alternative scheme,
provided that the activation of Factor V by
either activated Factor \lII or thrombin is assu-
med. A great deal of experimental evidence
appears to support the hypotheses that prothrom-
binase is a complex structure consisting of
activated factor X and activated FactorV bound to
a phospholipid surface, the former by a bond via
e Ca++ ion, the latter by a hydrophobic bond.
This concept is shown in Fig. 4.
The most compelling points on which this view
is based are:
(a) Anyone of the three components, Factor Xu,
Factor Vu, or phospholipid, can be present in
a limiting amount. The concentration of
prothrombinase is then determined by the
concentration of this limiting componentls.
(b) An excess of phospholipid has an inhibitory
action, bly presuma because this excess results
I
Fig. 4. The happening by which thrombin is generated.
in a surface area too large for Factors X and V
to cover adequately. A possible explanation of
the strongly inhibitory action ofcertain specific
phospholipids28 could lie in the fact that these
phospholipids bind only one ofthe two factors
and thus withdraw a reactant from the mix-
ture.
(c) From a mixture having prothrombinase
activity, no Factor X, Factor V, or phospholi-
pids can be separated without loss of that
activityls.
(d) Enzyme kinetics of one-stage estimations of
Factors II, V, X, and phospholipid show that
the Factor II- converting enzyme must be a
combined product of Factors X, V, and phos-
pholipid, and also that this product must be a
labile one that is actively degraded during the
clotting process. This is another indication
of the importance of the inactivating processes
during clotting2s.
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(e) Experiments on the generation of prothrom-
binase from purified bovine Factor V, Factor
X, and phospholipid show that the kinetics
involved are compatible with the concept of
prothrombinase as a combination product of
the reactants but not with the concept implying
the activation of Factor V by Factor Xn'2o.
Therefore the results of these experiments
support those mentioned under d. Moreover,
it has been shown that in a purified system
prothrombinase is about ro times more stable
than it is in plasma, which supports the as-
sumption of a prothrombinase inactivator in
plasma.
(f) Activated Factor X can be shown to attach to
phospholipid when Ca++ is present. Factor V
binds to phospholipid in the absence of Ca++.
Excess Ca++ prevents the binding ofFactor V
to phospholipid5l,52'53 (Table II).
Activated Factor X has been shown by Mlc-
TARLANEsA and EsttouF and Wn ttausls to
originate from Factor X by the action of Russnr,'s
Viper Venom or Factor \lllu. HlN.LnANal'l8 hac
shown that one molecule of Factor X gives rise
to two molecules of Factor X, when Ca++ions
are present.
Recent experiments in our laboratory, perfor-
med in collaboration with M. J. P. KlrrN, have
shown that Factor IXu, like Factor Xu, is bound
to phospholipid with the aid of Ca++ions (Table
lI, ref . zz) and that Factor VIII, like Factor V, is
bound to phospholipid via a kind of binding that
is hampered by an excess of Ca++ions.
It has long been known that phospholipid and
Ca++ play a role in coagulation at the level of
Factors VIII and IX as well as at the level of
T.q.sls II: AosorpnoN oF cr-orrrNc FAcroRs oNTo pHospHol-rprD uNDBR INFLUENcE or Cl++roNs*
Ca++
concentrates
(mM)
Percentage adsorbed of
Factor V Factor VIII Factor IX Factor X
I
50
100
J T
59
77
23
45
7 l
67
4l
J
65
2
< t
* Serum was the source of Factor IX and Factor X; BaSOn-adsorbed plasma was the source of Factor V and
Factor MII. The phospholipid used was Inostithin (Asc. Concentrates Ltd.). For further experimental details
see ref. 62.
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.Factors V and X. Now that the strikingly similar
mode of interaction of these two pairs of factors
with phospholipid and Ca++ has been observed
and a reasonable assumptioncanbe made concer-
ning the exact mode of interaction between Fac-
tors V and X, phospholipid, and Ca++, it requires
only a little imagination to postulate that a com-
plex with the enzymatic activity to convert Factor
X into its acitvated form is constituted by Factor
IXu and Factor VIII together, adsorbed onto a
phospholipid micelle surface. Because of its
enzymatic activity, the complex is termed ten-ase
in the reaction equations below.
From the foregoing a general pattern of the
interaction of clotting factors emerges in which
the enzlnnatic activity is exerted by clusters of two
factors adsorbed onto phospholipid rather than
by activated clotting factors alone.
Fig. 5. A clotting scheme anno 1967. In this diagram
the arrows indicate "action upon" rather then "con-
vertion into"; the.thigkness of the arrows indicates
theif relative imoortance.
An over-all scheme based on this principle is
given in Fig. 5, This figure also indicates the role
conoeivably played by Factor VII in the intrinsic
pathway. The horizontal arrow between Factor
VII and Factor IX refers to a finding by Josso and
Pnou-WanrBrrnzl , indicating that under certain
circurnstances Factor VII. may act on Factor fX.
'Written in reaction equations, the process
looks like this:
Folia Med.Neerl.,. rri ( 1967)
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contact
XII - -> XIIA
XIIa + XI -) contact product
contact product or tissue factor
vIIa
ten-ase or VII'
| 2Xa
Xu or YlIu or thrombin
Xu * Vu * ph.lip. * Ca++-)prothrombinase (F)
prothrombinase
il -_____-_>- thrombin
contact product
IX -_________>. IXu
thrombin
VIII -)' !11tu
IX. * VIII. * ph.lip. * Ca++ -----> ten-ase (K)
It is interesting to speculate upon the role of
Factor V in the prothrombinabe complex.
Experiments reported by EsNourl2 indicate that
the active center of the prothrombinase complex
is located on the Factor Xu molecule. This is the
more feasible because Factor Xu appears to be an
esterase of the serine-esterase family whereas of
Factor Vu no such properties could be found. This
suggests that Factor Vu might act by providing
means to achieve a more efficient handling of
the substrate (:protfuombin) by the active
center. When this is true, it would, to our
knowledge, be the first recorded instance of
an enzyme (prothrombinase) consisting of two
(A)
(B)
I
I
I(c) I
I
I
VII
(E)
(G)
(H)
va
(D)
(r)
different protein moieties viz. the "active-site
carrier" (Factor X) and the "para-enzyme"
(Factor V). Ten -ase might be a second example
of this kind of enzyme.
In the above we have not taken into account the
possible interactions between the Factors Xu and
Vu after adsorption. Of course such interactions
do exist, but thus far we have not been able to
estimate them.
Two relevant points remain to be discussed.
The first is the inactivation of thrombin. Once
thrombin has been formed and has acted on
fibrinogen, it can remain attached to the product
molecule during polymerizationso. Fibrin has a
wel-defi nedthrombin-absorbing action. Moreover,
free thrombin in plasma is inactivated in a reac-
tion with a plasma protein known as antithrombin
IIl. The affinity of thrombin for antithrombin III
is, however, considerably smaller than the affinity
of thrombin for fibrinogen, so that without hinder-
ing the conversion of fibrinogen, antithrombin III
can remove free thrombin from clotting b1ood26.
Partially antithrombin III- deflcient patients have
been describedll. These patients develop severe
thrombotic complications at the slightest pro-
vocation.
The second point is that the product formed by
polymerization of flbrin monomers is not a firm
clot; unlike a normal clot, for instance, it is
soluble in 5 M urea. In the polymerizate, Factor
XIII', the fibrin-stabilizing factor, constructs
bridges between adjacent amino acid chains.
Factor XIII' originates from Factor XIII by the
action of thrombin. The bridging is brought
about by catalization of an interaction between
amino group containing amino acid residues in
parallel fibrin strandss'z. (Fig. 6, 7).
In conclusion it may be said that blood coagu-
lation is an extremely complicated process. The
complications have a magic charm for the specia-
lized investigator and often appear as uncanny
black magic to the outsider, who may derive only
a limited amount of comfort from the fact that
oflate much ofthe confusion has been replaced by
recognized complexity, even more limited because
the recent views and hypotheses discussed in this
article are liable to be corrected and extended over
and over again in the future. The only real com-
fort f,or the layman and specialist alike may be
that "Truth comes out of error more readily than
out of confusion" (FuNcrs B,q,coN).
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Fig. 6. Schematic representation of the polymerization
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(Factor XIID.
Those who object intuitively to the jdea of so
complicated a mechanism for so simple a funition
as blood clotting are reminded that circulation,
which is well known to be provided with a most
intricate mechanism for maintaining flow, intra-
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vascular volume, and pressure, may well need a
sophisticated device for the prevention ofleakage
or untimely obstruction.
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